NewAmsterdam Pharma (NAMS) EBITDA (2023 - 2026)

NewAmsterdam Pharma has reported EBITDA for 4 years, with the latest figure at -$58.4 million in Q1 2026.

• Quarterly EBITDA rose 15.24% year-over-year to -$58.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$215.2 million (down 13.41% YoY) and the FY2025 annual result came in at -$225.7 million, down 28.02% from the prior year.
• EBITDA advanced to -$58.4 million in Q1 2026 per NAMS's latest filing, from -$66.0 million in the prior quarter.
• Over five years, EBITDA peaked at -$25.0 million in Q3 2024 and troughed at -$68.9 million in Q1 2025.
• A 4-year average of -$49.5 million and a median of -$51.1 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2025: EBITDA soared 49.55% in 2024, then sank 120.55% in 2025.
• Over 4 years, EBITDA stood at -$51.1 million in 2023, then advanced by 15.36% to -$43.2 million in 2024, then sank by 52.63% to -$66.0 million in 2025, then climbed by 11.46% to -$58.4 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$58.4 million, -$66.0 million, and -$55.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.